Factors Examined for Time to First Rx for Biologic DMARD in RA
Longer time to receipt more likely with older age, male sex, greater distance to nearest rheumatologist.
Longer time to receipt more likely with older age, male sex, greater distance to nearest rheumatologist.
The FDA has approved Avsola (infliximab-axxq; Amgen), a biosimilar to Remicade (infliximab; Janssen Biotech).
The FDA has approved RediTrex (methotrexate injection; Cumberland) for the management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis, who are intolerant of or had an inadequate response to first-line therapy.
The Food and Drug Administration (FDA) has approved Abrilada (adalimumab-afzb; Pfizer), a biosimilar to Humira (adalimumab; AbbVie).
Risk for preterm delivery higher in women with RA, Crohn disease regardless of adalimumab exposure.
AbbVie announced positive topline data from the phase 3 SELECT-PsA 2 trial of upadacitinib (Rinvoq) in patients with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response to ≥1 biologic disease modifying anti-rheumatic drugs (bDMARDs).
Filgotinib is an investigational, oral selective JAK1 inhibitor.
Improved disease control, remission, functional capacity for TNF or non-TNF plus methotrexate
The approval was based on data from five phase 3 trials (the SELECT program) involving approximately 4400 patients with moderate to severe RA, including those who failed or were intolerant to biologic disease-modifying antirheumatic drugs.
The Food and Drug Administration (FDA) has approved changes to the prescribing information for tofacitinib to include new warnings, including a Boxed Warning, regarding an increased risk of blood clots and death associated with the 10mg twice daily regimen. The update comes after a review of data from an ongoing safety clinical trial of tofacitinib…